Free Trial
ASX:RCE

Recce Pharmaceuticals (RCE) Stock Price, News & Analysis

Recce Pharmaceuticals logo

About Recce Pharmaceuticals Stock (ASX:RCE)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
630,087 shs
Average Volume
N/A
Market Capitalization
$104.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Recce Pharmaceuticals Ltd, a biotechnology company, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, the company engages in R327 Intravenous which provides serious/life-threatening bacterial infections, including sepsis which is in the phase 1 trial; urinary tract infections, including urosepsis; rapid infusions sepsis in the phase 2 trial; and R327 Topical offers wound infections, including infected burns; and diabetic foot ulcer infections in Phase 2 trails. Further, the company operates various pre-clinical programs, such as Mycobacterium abscessus which is in phase 1 clinical trial; bacterial sinusitis; and additional TBA. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Receive RCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recce Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCE Stock News Headlines

Recce Pharmaceuticals Updates Securities Issue Timeline
Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.
See More Headlines

RCE Stock Analysis - Frequently Asked Questions

Recce Pharmaceuticals Ltd (ASX:RCE) announced its earnings results on Wednesday, February, 27th. The company reported ($0.01) earnings per share (EPS) for the quarter. Recce Pharmaceuticals had a negative net margin of 741.65% and a positive trailing twelve-month return on equity of 392.94%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Recce Pharmaceuticals investors own include ASE Technology (ASX), FlexiGroup Limited (FXL.AX) (FXL), Immutep (IMMP), Mavenir (MVNR), Cronos Group (CRON), Cree (CREE) and Caladrius Biosciences (CLBS).

Company Calendar

Last Earnings
2/27/2019
Today
5/03/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:RCE
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-17,660,000.00
Net Margins
-741.65%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.03 million
Price / Cash Flow
13.57
Book Value
A($0.05) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$104.34 million
Optionable
Not Optionable
Beta
1.05
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (ASX:RCE) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners